公开(公告)号：US20230278965A1

公开(公告)日：2023-09-07

申请号：US18011469

申请日：2021-06-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ae Nim PAE ,  Yun Kyung KIM ,  Sang Min LIM ,  Sungsu LIM ,  Haeun LEE ,  Woo Seung SON ,  Hye Yeon LEE

IPC: C07D241/24 ,  C07D213/75 ,  C07D401/14 ,  C07D409/12 ,  C07D417/12 ,  C07D413/12 ,  C07D237/08 ,  C07D333/60 ,  C07D277/56

CPC classification number: C07D241/24 ,  C07D213/75 ,  C07D401/14 ,  C07D409/12 ,  C07D417/12 ,  C07D413/12 ,  C07D237/08 ,  C07D333/60 ,  C07D277/56

Abstract: Provided are novel carbonohydrazonoyl dicyanide compounds including two or more aryl or heteroaryl groups connected via a linker and uses thereof.

公开(公告)号：US20180057527A1

公开(公告)日：2018-03-01

申请号：US15687203

申请日：2017-08-25

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  POSTECH ACADEMY-INDUSTRY FOUNDATION

Inventor： Gyo Chang KEUM ,  Eunice Eun Kyeong KIM ,  Sung Key JANG ,  Hee Sun KIM ,  Ae Nim PAE ,  Hua LI ,  Jin Hyeong PARK ,  Jin Sook KWAK

IPC: C07K5/065 ,  C07K5/062

Abstract: The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.

公开(公告)号：US20140114067A1

公开(公告)日：2014-04-24

申请号：US14048979

申请日：2013-10-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ae Nim PAE ,  Sun Joon MIN ,  Eun Joo ROH ,  Ha Yun YANG ,  Tae Hoon KIM ,  Beoung Gun PARK ,  Yong Seo CHO

IPC: C07D413/06 ,  C07D403/06 ,  C07D401/06 ,  C07D233/26

CPC classification number: C07D413/06 ,  C07D235/08 ,  C07D235/10 ,  C07D235/12 ,  C07D235/14 ,  C07D235/28 ,  C07D401/06 ,  C07D403/06 ,  C07D403/12

Abstract: Provided are a benzimidazole derivative modulating mitochondrial functions and having pharmaceutical activity as a neuro-protective agent, and a pharmaceutical composition including the compound as an active ingredient.

Abstract translation: 提供调节线粒体功能并具有作为神经保护剂的药物活性的苯并咪唑衍生物和包含该化合物作为活性成分的药物组合物。

公开(公告)号：US20230295095A1

公开(公告)日：2023-09-21

申请号：US18011459

申请日：2021-06-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ae Nim PAE ,  Yun Kyung KIM ,  Sang Min LIM ,  Sungsu LIM ,  Haeun LEE ,  Woo Seung SON ,  Hye Yeon LEE

IPC: C07D217/24 ,  C07D235/26 ,  C07D263/58 ,  C07D277/68 ,  C07D215/227 ,  C07D471/04

CPC classification number: C07D217/24 ,  C07D235/26 ,  C07D263/58 ,  C07D277/68 ,  C07D215/227 ,  C07D471/04

Abstract: Provided are novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and uses thereof.

公开(公告)号：US20140343295A1

公开(公告)日：2014-11-20

申请号：US14013487

申请日：2013-08-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ghil Soo NAM ,  Kyung Il CHOI ,  Ae Nim PAE ,  Seon Hee SEO ,  Hyun Ah CHOO ,  Gyo Chang KEUM ,  Jung Hyun KIM

IPC: C07D403/12

CPC classification number: C07D403/12 ,  A61K31/4155

Abstract: The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.

Abstract translation: 本发明涉及可用作钙通道阻滞剂的6-吡唑基氨基-3-取代的氮杂双环[3.1.0]己烷衍生物，其药学上可接受的盐，以及该化合物治疗疾病的钙通道抑制作用的医学用途。

公开(公告)号：US20230278963A1

公开(公告)日：2023-09-07

申请号：US18011460

申请日：2021-06-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ae Nim PAE ,  Yun Kyung KIM ,  Sang Min LIM ,  Sungsu LIM ,  Haeun LEE ,  Woo Seung SON ,  Hye Yeon LEE

IPC: C07D237/14

CPC classification number: C07D237/14

Abstract: Provided are novel oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compounds and uses thereof.

公开(公告)号：US20210317083A1

公开(公告)日：2021-10-14

申请号：US17268958

申请日：2019-08-19

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ki Duk PARK ,  Ae Nim PAE ,  Sang Min LIM ,  Jong Hyun PARK ,  Ji Won CHOI ,  Siwon KIM ,  Hyeon Jeong KIM ,  Seul Ki YEON

IPC: C07D213/52 ,  C07F9/40

Abstract: The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

公开(公告)号：US20150329533A1

公开(公告)日：2015-11-19

申请号：US14632839

申请日：2015-02-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ghil Soo NAM ,  Kyung Il CHOI ,  Jung Hyun KIM ,  Ae Nim PAE ,  Jin Ri HONG ,  Jae Kyun LEE

IPC: C07D417/14 ,  C07D401/12 ,  C07D417/06 ,  C07D231/12

CPC classification number: C07D231/12 ,  C07D401/12 ,  C07D417/06 ,  C07D417/14

Abstract: Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.

Abstract translation: 本文公开了可用作钙离子通道阻断剂的N-（吡唑基甲基）芳基磺酰胺衍生物及其药学上可接受的盐，其药物用途为其钙离子通道阻断作用的治疗剂。

公开(公告)号：US20140206876A1

公开(公告)日：2014-07-24

申请号：US13943019

申请日：2013-07-16

Applicant: Korea Institute of Science and Technology

Inventor： Sun Joon MIN ,  Yong Seo CHO ,  Ae Nim PAE ,  Eun Jeong LIM ,  Ji Yeong KIM ,  Myung Hee SON ,  Jae Kyun LEE

IPC: C07D215/06 ,  C07D215/20 ,  C07D401/06

CPC classification number: C07D215/06 ,  C07D215/20 ,  C07D401/06

Abstract: Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).

Abstract translation: 本发明提供具有mGluR5拮抗活性的2-（取代乙炔基）喹啉衍生物及其药学上可接受的盐。 本发明的化合物可用作治疗和预防mGluR5受体介导的疾病如阿尔茨海默氏病，老年性痴呆，帕金森病，L-DOPA诱导的运动障碍，亨廷顿舞蹈病，肌萎缩性侧索硬化，多发性硬化，精神分裂症 ，焦虑症，抑郁症，神经性疼痛，药物依赖，脆性X综合征，自闭症，偏头痛和胃食管反流病（GERD）。

公开(公告)号：US20230406812A1

公开(公告)日：2023-12-21

申请号：US18036847

申请日：2021-11-12

Applicant: INSTITUTE FOR BASIC SCIENCE ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chang Jun LEE ,  Heejung CHUN ,  Woojin WON ,  Ki Duk PARK ,  Jong Hyun PARK ,  Ae Nim PAE ,  Ji Won CHOI ,  Elijah LEE ,  Sun Jun PARK ,  Hyeon Jeong KIM ,  Yoowon KIM ,  Byung Eun KIM ,  Siwon KIM

IPC: C07C211/53 ,  A23L33/10 ,  A61P25/28

CPC classification number: C07C211/53 ,  A61P25/28 ,  A23L33/10

Abstract: The present invention provides a novel aminoaromatic compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition that is for preventing or treating neurodegenerative diseases and comprises same as an active ingredient, and a health functional food composition for preventing or ameliorating neurodegenerative diseases.